To The Moon

$Addvalue Tech(A31.SI)$ 0.3 Target Price Simply Wall St Value Rating: ★★★★★★ Overview: Addvalue Technologies Ltd is an investment holding company that offers satellite-based communication and digital broadband products and solutions across Europe, the Middle East, Africa, North America, and the Asia Pacific with a market cap of SGD593.02 million. Operations: Revenue for Addvalue Technologies primarily comes from its Communications Equipment segment, totaling $18.58 million.    Addvalue Technologies, a compact player in the space communication sector, has shown impressive growth with earnings surging 300.6% over the past year, outpacing the communications industry average of 7.4%. The company's strategic focus on its Space Connectivity

$ValueMax(T6I.SI)$ 2 Target Price by WallStreet analyst. ValueMax Group (SGX:T6I) Simply Wall St Value Rating: ★★★★ Overview: ValueMax Group operates in pawnbroking, moneylending, and the retail and trading of jewellery and gold, with a market capitalization of approximately SGD 0.48 billion. Operations: The company generates revenue primarily from retail and trading of jewellery and gold, alongside pawnbroking and moneylending services. The gross profit margin has shown a notable trend, increasing from 6.65% in mid-2014 to 28.45% by the end of 2025. Operating expenses have been a consistent component of the cost structure, with general and administrative expenses being significant contributors. PE: 5.5x ValueMax Group, a small company in Asia,

$CNMC Goldmine(5TP.SI)$ 2 Target Price. CNMC Goldmine(5TP) will upsurge in coming weeks due to discovery of rare metals deposits, global geopolitical tension in middle-east & latin American, distrust in U.S treasury bonds and it's currency. China Nonferrous Metal Mining Group (CNMC) has recently discovered rare metal earth deposits, on top of GOLD ores, in it's Sokor Gold field, Malaysia. Production Expansion: CNMC Goldmine's carbon-in-leach (CIL) plant expansion has increased daily processing capacity to 800 tonnes, supporting higher output potential. - Earnings Growth: Strong FY-2025 earning growth, with a 40% net profit increase in Year-2025 PATMI to US$42 million. *Analyst Price Target for CNMC:* - Phillip Securities has a BUY rating wit

$REALLOYS INC(ALOY)$  

$IX Biopharma(42C.SI)$ 0.8 Target Price. --Ix Biopharama Medical Breakthrough-- iX Biopharma achieved a major medical and commercial breakthrough with Wafermine, its patented sublingual (under-the-tongue) ketamine wafer for non-opioid acute pain management.   --The Core Technology-- WaferiXFast Absorption: Wafers dissolve sublingually in minutes, letting active ingredients enter the bloodstream directly and bypass the gut. High Bioavailability: Provides a needle-free, predictable alternative to intravenous  infusions or standard oral pills. Drug Repurposing: Applies the delivery system to central nervous system agents and other urgent indications.  --Key Pipeline & Commercial Milestones-- Backed by a US$40.95 million cont

$PanUnited(P52.SI)$ 2 Target Price. *Growth Catalysts for Pan-United Corporation (P52.SI)* Pan-United is Singapore's  largest ready-mixed concrete producer, and analysts see several drivers supporting growth into 2026-2027: 1). Singapore Construction Demand Surge - *Public sector pipeline*: New HDB developments, Cross Island Line, Tuas Mega Port, and institutional projects are expected to drive ∼55% of total construction demand. - *RMC volume growth*: Ready-mix concrete demand is projected to jump 34% from 13.4 million m³ in 2024 to 18 million m³ by 2027. - Analysts forecast EPS for Pan-United to grow 6-22% in FY26-FY27 on stronger offtake volume. *2. ESG & Low-Carbon Concrete Leadership* - Pan-United specializes in low-carbon concrete

$IX Biopharma(42C.SI)$ 0.8 Target Price. --iX Biopharma Ltd(42C) Growth Catalysts-- Shift towards commercialisation of WaferiX subligual delivery of drugs could bump up revenue by as much as 250% in FY-2026, backed by planned capacity expansion. Out-licensing of the sublingual ketamine wafer, Wafermine, for Phase 3 development will be a major catalyst and expected to turn iX Biopharma profitable in long-term.  Specialty pharmaceutical and nutraceutical drugs will benefit from the planned six-fold increase in production capacity to meet the expected surge in demand. Investment Merits Out-licensing world's first sublingual ketamine formula, Wafermine, for Phase 3 development is a near-term catalyst. Since the completion of its end-of-Ph

$REALLOYS INC(ALOY)$ $18 Target Price -- About Realloys Inc (ALOY)-- RealLoys Inc is at the centre of a major US policy push to build a domestic rare-earth supply chain, which has driven significant  bullish momentum and impact on it's defence and eletronic sector. -- Growth Catalysts for ALOY-- 1). Trump Key Minerals & Rare Earth Company listing in Aug-2026 President Trump hosted 200+ mining executives and announced ~US$3 billion in federal funding for critical minerals. ALOY surged ~15% on the day, alongside the broader US rare-earth sector. Trump Public Endorsement of ALOY 08-Aug-2026 In a live interview, Trump explicitly named ALOY as a core upstream supplier for the US permanent-magnet supply chain, stating it would r

$Sheng Siong(OV8.SI)$  $3.8 Target Price.  Most investors spend too much time thinking about when to buy and when to sell. But what if selling was not an option? Suppose the Singapore market closed tomorrow and stayed shut for the next 10 years. Which businesses would you still be happy to own? Warren Buffett once said investors should buy businesses they are happy to own for years, not days. The one Singapore that pass the test is as follows: Sheng Siong (SGX: OV8) – The Defensive Consumer Business Why I'd Hold It for 10 Years There are retailers who do not have to reinvent themselves to continue growing. In hard times, people are more careful about their expenses, and that is what distinguishes Sheng Siong f

$IX Biopharma(42C.SI)$ $0.8 Target Price --About IX Biopharma (42C.SI)-- iX Biopharma Ltd (SGX: 42C) is a specialty pharmaceutical and nutraceutical company focused on developing, manufacturing, and commercializing products using its proprietary sublingual drug delivery technologies. Its core growth catalysts center on commercial technology expansion, U.S. market entry, and joint venture/licensing opportunities. --Growth Catalysts for iX Biopharma-- 1). Commercialization & Out-Licensing of WaferiX®: Monetization of its patented sublingual wafer platform (WaferiX®, WaferlogiX) via out-licensing deals, tech transfers, and manufacturing agreements for repurposed pharmaceutical molecules (such as Wafermine for pain management and Wafesil f